Global Needle-free Injection System Industry Market 2015, Finds New Report

2015 Market Research Report on Global Needle-free Injection System Industry is a professional and deep research report in this field.

For overview analysis, the report introduces Needle-free Injection System basic information including definition, classification, application, industry chain structure, industry overview, policy analysis, and news analysis, etc.

For international and China market analysis, the report analyzes Needle-free Injection System markets in China and other countries or regions (such as US, Europe, Japan, etc) by presenting research on global products of different types and applications, developments and trends of market, technology, competitive landscape, and leading suppliers’ and countries’ 2009-2014 capacity, production, cost, price, profit, production value, and gross margin. For leading suppliers, related information is listed as products, customers, application, capacity, market position, and company Contact information, etc. 2015-2020 forecast on capacity, production, cost, price, profit, production value, and gross margin for these markets are also included.

For technical data and manufacturing plants analysis, the report analyzes Needle-free Injection System leading suppliers on capacity, commercial production date, manufacturing plants distribution, R&D status, technology sources, and raw materials sources.

For industry chain analysis, the report covers Needle-free Injection System upstream raw materials, equipment, downstream client survey, marketing channels, industry development trend and proposals, which more specifically include valuable information on Needle-free Injection System key applications and consumption, key regions and consumption, key global distributors , major raw materials suppliers and contact information, major manufacturing equipment suppliers and contact information, major suppliers and contact Information, key consumers and contact information, and supply chain relationship analysis.

This report also presents Needle-free Injection System product specification, manufacturing process, and product cost structure etc. Production is separated by regions, technology and applications. In the end, the report includes Needle-free Injection System new project SWOT analysis, investment feasibility analysis, investment return analysis, and development trend analysis.

In conclusion, it is a deep research report on global Needle-free Injection System industry. Here, we express our thanks for the support and assistance from Needle-free Injection System industry chain related technical experts and marketing engineers during research team’s survey and interviews.

Spanning over 160 pages, “2015 Market Research Report on Global Needle-free Injection System Industry” report covering the Needle-free Injection System Industry Overview, Needle-free Injection System International and China Market Analysis, Needle-free Injection System Technical Data and Manufacturing Plants Analysis, Needle-free Injection System Production by Regions By Technology By Applications, Needle-free Injection System Manufacturing Process and Cost Structure, 2009-2014 Needle-free Injection System Productions Supply Sales Demand Market Status and Forecast, Needle-free Injection System Key Manufacturers Analysis, Up and Down Stream Industry Analysis, Needle-free Injection System Marketing Channels Analysis, 2015-2020 Needle-free Injection System Industry Development Trend, Needle-free Injection System Supply Chain Relationship Analysis, Needle-free Injection System New Project Investment Feasibility Analysis, Global Needle-free Injection System Industry Research Conclusions.

For further information on this report, please visit- http://mrr.cm/4qN

Find all Medical Devices Report at: http://www.marketresearchreports.com/medical-devices

Global IVIG Industry Market 2015, Finds New Report

2015 Deep Research Report on Global IVIG Industry is a professional and depth research report on Global IVIG industry

For overview analysis, the report introduces IVIG basic information including definition, classification, application, industry chain structure, industry overview, policy analysis, and news analysis, etc

For international and China market analysis, the report analyzes IVIG markets in China and other countries or regions (such as US, Europe, Japan, etc) by presenting research on global products of different types and applications developments and trends of market, technology, and competitive landscape, and leading suppliers and countries’2009-2014 capacity, production, cost, price, profit, production value, and gross margin. For leading suppliers, related information is listed as products, customers, application, capacity, market position, and company contact information, etc. 2015-2020 forecast on capacity, production, cost, price, profit, production value, and gross margin for these markets are also included.

For technical data and manufacturing plants analysis, the report analyzes IVIG leading suppliers on capacity, commercial production date, manufacturing plants distribution, R&D Status, technology sources, and raw materials sources.

This report also presents product specification, manufacturing process, and product cost structure etc. Production is separated by regions, technology and applications. Analysis also covers upstream raw materials, equipment, downstream client survey, marketing channels, industry development trend and proposals.

In the end, the export includes IVIG new project SWOT analysis, investment feasibility analysis, investment return analysis, and development analysis. In conclusion, it is a deep research report on Global IVIG industry. Here, we express our thanks for the support and assistance fromIVIG industry chain related technical experts and marketing engineers during Research Team’s survey and interviews.

Spanning over 163 pages, “2015 Deep Research Report on Global IVIG Industry” report covering the IVIG Industry Overview, Global IVIG Market Status Analysis, Major Regions IVIG Market Status Analysis, Major Countries IVIG Market Status and Analysis, IVIG Key Manufacturers Analysis, IVIG Industry Chain and Marketing Channels Analysis, IVIG Industry Segment Market Analysis, IVIG Industry Development Trend, IVIG New Project Investment Feasibility Analysis, Global IVIG Industry Research Conclusions.

For further information on this report, please visit- http://mrr.cm/4Ta

Find all Pharmaceutical Manufacturing Report at:

http://www.marketresearchreports.com/pharmaceutical-manufacturing

Celiac Disease Treatment Market to Grow More than Tenfold to $551 Million by 2023, Finds New Report

The celiac disease treatment market value will expand more than tenfold from an estimated $49.6 million in 2013 to $551.1 million by 2023, at an impressive Compound Annual Growth Rate (CAGR) of 27.24%, according to new report.

The company’s latest report states that the US will continue to account for almost all of the celiac disease therapeutics space, which also includes the five European countries (5EU) of France, Germany, Spain, Italy and the UK. The US share will slip slightly from 99% in 2013 to just under 98% by the end of the forecast period.

Senior Analyst covering Immunology, says that the market will be driven primarily by the potential introduction of two novel pipeline drugs, Alba/Teva’s larazotide acetate and Alvine/AbbVie’s latiglutenase, which are designed to be used as adjunctive treatments to the current standard of care, a Gluten-Free Diet (GFD).

Senior Analyst comments: “Larazotide acetate is forecast to launch in the US in Q1 2018, with the key competitive advantage of targeting the majority of the disease population, compared with the 4–7% of refractory patients, who are currently treated with generics including steroids and immunosuppressants.

“In Q1 2019, larazotide acetate is expected to launch in the 5EU, while latiglutenase may potentially launch in the US. These pipeline drugs are forecast to increase sales in the six major markets (6MM) from $49.6 million in 2013 to $289.9 million by the end of 2019.”

Senior Analyst adds that Q1 2020 may see the launch of latiglutenase in the 5EU, thereby boosting the 6MM sales further to $343.3 million, with a steady incline up to $551.1 million by 2023.

Despite the anticipated impact of these novel drugs, there are a number of barriers to growth in the celiac disease treatment market, such as limited physician and patient awareness of the condition and a lack of confidence in pipeline drugs compared with a GFD.

Senior Analyst continues: “Improved physician education concerning GFDs and developments in the gluten-free food market may refine the standard of care and this, in turn, may deter physicians from prescribing adjunctive treatments.”

OpportunityAnalyzer: Celiac Disease - Opportunity Analysis and Forecast to 2023 report provides annualized celiac disease therapeutics market revenue, annual cost of therapies and forecasts for five years to 2018 and ten years to 2023 in the US and five major European markets (Germany, France, Spain, Italy and the UK). Key topics covered include strategic product assessment, market characterization, unmet needs, research and development strategies, pipeline analysis and clinical trial design.

This report was built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis conducted by Publisher’s team of industry experts.

For further information on this report, please visit- http://mrr.cm/4Te

Find all Pharma and Healthcare Report at: http://www.marketresearchreports.com/pharma-healthcare

$350 Billion Opportunity in Global Generic Drugs Market, Finds New Study

A generic drug is a pharmaceutical product, usually intended to be interchangeable with an innovator product, that is manufactured without a license from the innovator company and marketed after the expiry date of the patent or other exclusive rights.

Already prevalent in the U.S., Europe and much of the developing world, generic drugs are now finding their way into previously untapped markets such as Japan, largely driven by regulatory efforts to reduce healthcare costs.

Publisher estimates that the market for generic drugs will account for nearly $350 Billion in revenue by the end of 2015. Despite challenges relating to quality control and legal concerns, the market is poised for significant growth in the coming years. The market is expected to grow at a CAGR of 12% between 2015 and 2020, driven by growth in both established and developing markets.

The “Generic Drugs Market: 2015 – 2030 – Opportunities, Challenges, Strategies & Forecasts” report presents an in-depth assessment of the generic drugs ecosystem including technology, economics, key trends, market drivers, challenges, investment potential, regulatory landscape, leading therapies, opportunities, future roadmap, value chain, ecosystem player profiles and strategies. The report also presents market size forecasts for generic drugs from 2015 through to 2030. The forecasts are segmented for over 10 therapeutic areas, 3 brand classifications, 5 regions and 25 leading countries.

The report comes with an associated Excel datasheet suite covering quantitative data from all numeric forecasts presented in the report.

Key Findings:

The report has the following key findings:

• Generic drugs will account for nearly $350 Billion in revenue by the end of 2015. The market is further expected to grow at a CAGR of 12% over the next five years.
• As the market consolidates, larger players continue to grow their market share on the heels of acquisitions and mergers. Well established players are particularly keen to capitalize on joint ventures in untapped markets such as Japan.
• In order to overcome low margins, some generic drug manufacturers are venturing into the super generics opportunity. Sold for a significantly higher price than their pure generic counterparts, super generics account for 18% of all spending on generic drugs.
• In a bid to control costs and expand their global reach, generic drug manufacturers are complementing their existing manufacturing and R&D locations with sites in low cost countries such as India, China and Russia.
• Driven by the cost saving potential of biosimilar drugs, a number of countries have established regulatory pathways for their approval. We estimate that approved biosimilar drugs will account for more than $20 Billion in revenue by the end of 2020.

Topics Covered:

• The report covers the following topics:
• Generic drugs ecosystem
• Market drivers and barriers
• Technology, economics and key trends
• Pure, branded and super generics
• Analysis of key therapeutic areas and leading generic drugs
• Regulatory landscape of generic drugs throughout the globe
• Industry roadmap and value chain
• Profiles and strategies of over 130 leading ecosystem players, including generic and innovator drug manufacturers
• Strategic recommendations for ecosystem players
• Market analysis and forecasts from 2015 till 2030

Historical Revenue & Forecast Segmentation:

Market forecasts are provided for each of the following submarkets and their subcategories:

Brand Classification

• Pure (Non-branded) Generics
• Branded Generics
• Super Generics

Therapeutic Area

• Antibiotics
• Cardiovascular & Hypertension
• CNS (Central Nervous System)
• Dermatology
• Diabetes
• Gastrointestinal
• Hormonal Drugs
• Oncology
• Pain Relief
• Respiratory
• Rheumatology
• Others

Regional Markets

• Asia Pacific
• Europe
• Middle East & Africa
• North America
• Latin & Central America

Country Markets

• Brazil
• Canada
• China
• Egypt
• France
• Germany
• Greece
• India
• Israel
• Italy
• Japan
• Mexico
• Netherlands
• Poland
• Portugal
• Russia
• Saudi Arabia
• South Africa
• South Korea
• Spain
• Switzerland
• Taiwan
• Turkey
• UK
• USA

Key Questions Answered:

• The report provides answers to the following key questions:
• How big is the generic drugs opportunity?
• What trends, challenges and barriers are influencing its growth?
• How is the ecosystem evolving by segment and region?
• What will the market size be in 2020 and at what rate will it grow?
• Which countries and submarkets will see the highest percentage of growth?
• How big is the market for generic cancer drugs?
• How does regulation impact the adoption of generic drugs?
• How will branded and super generics impact revenue prospects?
• Who are the key market players and what are their strategies?
• How will patent expirations of biologics impact the market?
• What are the future prospects of approved and non-approved biosimilar drugs?
• What strategies should generic and innovator drug manufacturers adopt to remain competitive?

Spanning over 249 pages, “The Generic Drugs Market: 2015 – 2030 - Opportunities, Challenges, Strategies & Forecasts” report covering the Introduction, An Overview of Generic Drugs, Regulatory Landscape, Drug Class Availability & Leading Therapies, Generic Drugs Industry Roadmap & Value Chain, Key Market Players, Market Analysis & Forecasts, Conclusion & Strategic Recommendations. The report covered companies are - , Abbott Laboratories, AbbVie, ACETO Corporation, Acino Holding, Actavis, Actelion, Adcock Ingram, Aesica Pharmaceuticals, Ajinomoto, Akron, Alexion Pharmaceuticals, Alfa Wasserman, Allergan

For further information on this report, please visit- http://mrr.cm/4Tc

Find all Pharma and Healthcare Reports at: http://www.marketresearchreports.com/pharma-healthcare

Personalized Medicine, Targeted Therapeutics and Companion Diagnostic Market 2015 - Strategic Analysis of Industry Trends, Technologies, Participants, and Environment, New Report Launched

Personalized Medicine. Targeted Therapeutics and Companion Diagnostic MarketA Strategic Analysis of Industry Trends, Technologies, Participants, and Environment” (published Feb 2015) provides you with a comprehensive account of the market size, segmentation, key players, SWOT analysis, influential technologies, and business and economic environments. The report is supported by over 270 tables & figures over 254 pages. 

Executive Summary:

“Personalized Medicine, Targeted Therapeutics and Companion Diagnostic Market 2015  Strategic Analysis of Industry Trends, Technologies, Participants, and Environment” by Kelly Scientific Publications is a cutting-edge comprehensive report on the personalized medicine industry and its impact on the health system. This report tackles the growing market interest in pharmacogenomics, companion diagnostics and the associated market environment. 

Individualized, targeted or personalized medicine aims to increase the efficacy of therapeutics via genetic testing and companion diagnostics. Personalized therapeutics and associated companion diagnostics will be more specific and effective thereby giving pharma/biotech companies a significant advantage to recuperate R&D costs. Personalized medicine will reduce the frequency of adverse drug reactions and therefore have a dramatic impact on health economics. Developmental and diagnostic companies will benefit from lower discovery and commercialization costs and more specific market subtypes. 

This report describes the current technologies that are propelling the personalized medicine and companion diagnostic market. It examines the current genetic diagnostic tests and companion diagnostic assays that are in use by the medical and pharmaceutical industry today. Current developments in personalized medicine and the pharmacogenomics revolution are discussed. The emerging trends that appear in key markets such as the US, UK, Germany and France are elucidated and analysed. This study reveals market figures of the overall personalized medicine market and also sub-market figures. Forecast projections and future growth rates are provided to give the reader a forthcoming perspective of this growing industry.

The study also provides a comprehensive financial and product review of key players in the personalized medicine industry. Strategic drivers and restraints of this market are revealed and market opportunities and challenges are identified. 

In summary, the personalized medicine and associated companion diagnostic market have huge opportunities for growth. This industry will revolutionize the healthcare system and will improve therapeutic effectiveness and reduce the severity of adverse effects. It has enormous potential for investment and the emergence of genetic-based in vitro diagnostics. 

The personalized medicine (global) market is presented as follows:

• By Company (e.g., 23andMe, AFFYMETRIX, ATOSSA GENETICS, NODALITY, CELERA, MYRIAD)
• By Geography (US, UK, EU)
• By Segment (Targeted therapeutics, Esoteric tests, Esoteric lab services)
• By Sub-market (Companion diagnostics, targeted cancer therapeutic, nutrition & wellness, medical technology, pharmacogenomics, consumer genomics, molecular diagnostics)

A wealth of financial data & business strategy information is provided including:

• Company financials, sales & revenue figures
• Business Model Strategies for Diagnostic, Pharmaceutical and Biotechnology Companies
• Business Model Strategies for Providers. Provider Systems and Academic Medical Centres
• Business Model Strategies for Payers & Governments
• Private and Public Funding and Personalized Medicine Reimbursement
• Revisions to Current Payment Systems and intellectual property
• How to Gain Market Penetration in the EU
• Cost-effectiveness and Business Value of Personalized Medicine
• Consumer genomics, molecular diagnostics and POC market
• Therapeutics and Companion Diagnostics (e.g., BRAC Analysis, Oncotype Dx , KRAS Mutations)
• Comprehensive account of company product portfolios & kits

SWOT, Economic & Regulatory Environment specifics include:

• Key strengths, weaknesses and threats influencing leading player position within the market
• Technologies driving the market (e.g., New-Generation Sequencing Technologies, Ultra-High Throughput Sequencing)
• Top fastest growing market segments and emerging opportunities
• Top pharmaceutical companies within the IPM by market share and revenue
• Comprehensive product portfolios, R&D activity and pipeline therapeutics
• M&A activity and future strategies of top personalized medicine pharmacos
• Personalized Medicine Regulation (UK, Germany, France, Spain, Italy)
• CE-marked Personalized Medicine/Diagnostic Tests
• FDA Advances in Personalized Medicine Regulation

What you will gain:

• An in-depth understanding of the global personalized medicine market and it’s environment
• Current market facts, figures and product lines of key players in the industry
• Emerging trends in key markets such as the US, UK, Germany and France
• Knowledge of how the personalized medicine market will integrate into the global healthcare market
• Technical insights into new generation sequencing technologies and ultra-high throughput sequencing
• Updates on bioinformatics, high throughput systems, genetic analysis kits, companion diagnostics and future technologies
• FDA approved pharmacogenetic tests and recognized biomarkers
• Information on key government and regulatory policies
• Strategies on how to adapt and restructure current business models to this industry

This report tackles key concerns to the personalized medicine market such as:

• Lack of regulatory policy and legislation in the US and Europe
• Reimbursement schemes and payers concerns
• Transition of investigational diagnostic assays and therapeutics to clinical practice
• Direct to consumer (DTC) test kits and implications for the public

Who should read this report?

• Pharmaceutical, biotechnology and diagnostic companies with an interest in personalized medicine
• Industry professionals and business strategists will discover key information to propel their policies
• Investors will gain inside information to dominant players in the industry and future forecasts
• Scientists will get a business perspective and industry insight into how scientific breakthroughs influence the market environment
• This report will tell you if the companies mentioned are:
• Strong, competitive players
• Pooling their resources for specific growth and therapeutic areas
• Investing strategically in R&D
• Have a history of strategic M&A activity

Spanning over 254 pages, “Personalized Medicine, Targeted Therapeutics and Companion Diagnostic Market 2015 - Strategic Analysis of Industry Trends, Technologies, Participants, and Environment” report covering the Executive Summary, Introduction and Background, Personalized Medicine Therapeutics and Associated Companion Diagnostics, Personalized Medicine and Integration into the Healthcare System, Private and Public Funding and Personalized Medicine Reimbursement, European Personalized Medicine Market – Payments and Investment, Personalized Medicine –Business Model Analysis, Personalized Medicine Main Industry Players, Personalized Medicine Industry Products and Kits, Personalized Medicine Market Analysis, Strengths and Advantages of Personalized Medicine, Restraints of the Personalized Medicine Market, Personalized Medicine and Regulatory Policies. The report covered companies are - 23andMe, Affymetrix, Astex Pharmaceuticals, Atossa Genetics, CuraGen, Celera Corporation (Quest Diagnostics), Celldex Therapeutics, deCode Genetics (Amgen), Illumina, Genelex, Myriad, Nodality, Qiagen, Admera Health (GeneWiz), Claritas Genomics

For further information on this report, please visit- http://mrr.cm/4To

Find all Diagnostics Reports at: http://www.marketresearchreports.com/diagnostics

Global Transdermal Drug Delivery Market to 2020, New Report Launched

 Global Transdermal Drug Delivery Market to 2020: Strategic Analysis, Technologies, Competitor Profiles, Financial Evaluation, Product Pipeline Assessment and SWOT Investigation

“GLOBAL & USA TRANSDERMAL DRUG DELIVERY MARKET TO 2020: Strategic Analysis, Technologies, Competitor Profiles, Financial Evaluation, Product Pipeline Assessment and SWOT Investigation” by Kelly Scientific Publications is a dedicated report on the transdermal drug delivery industry and its impact on the USA and global markets. 

This comprehensive report tackles problems that this vertical growing market faces and evaluates saturated sub-markets. A detailed outlay of its major players is performed including business strategy and future development analysis, merger and acquisition tactics, current product and pipeline entry evaluation and a detailed section on each player’s financial situation. This analysis determines the unmet needs of the transdermal drug delivery industry and specific niche areas of market entry.

The transdermal drug delivery market has substantial associations within the smoking cessation market, analgesics/pain market, generics market, neuropathic pain market and also the women’s health market. In the future it will enter the vaccine and gene therapy markets. Transdermal drug delivery is a complex area that has many driving factors including the unmet need for non-invasive drug delivery systems for pediatric, geriatric and dementia patients. 

This report describes the current technologies that are propelling the market space and emerging trials and pipeline agents that will make a significant impact on the industry. It examines the current transdermal delivery systems and how generic competition is allowing penetration of new players in the market and saturation of niche areas.

Financial figures of the drug delivery market and the transdermal drug delivery space are revealed in this report. Forecast projections and future growth rates are provided to give the reader a forthcoming perspective of this growing industry. The study also provides a comprehensive financial, business strategy and product review of key players in the transdermal drug delivery industry. Strategic drivers and restraints of this market are revealed and market opportunities and challenges are identified. 

In summary, the transdermal drug delivery market has huge opportunities for growth in the areas of dementia (Alzheimer’s & Parkinson’s Disease), generics, paediatrics and geriatrics. Currently the USA is the most prominent market place, followed by Europe, Asia and Emerging Markets. This report will reveal in-depth analysis of the industry and provide cutting-edge intelligence on the current and future spaces it will penetrate.

In 2014, the global drug delivery market (DDM) was worth just under $x billion, a significant jump from $x billion in 2010. The market grew steadily within this time period with a compound annual growth interest of x%. By the end of 2016, it is expected to be worth over $x billion, and make gains to over $x billion by 2020.

Today the US market holds just over x% share, and within the next five years Asian and Emerging market spaces will increase in size. By 2020, the Asian drug delivery market will surge past x%, compared to over x% in Europe. The US total drug delivery market will continue to maintain its x% share by 2020. 

Within the total drug delivery market exists the advanced DDM, which is further segmented into the following niche areas:

• Transdermal
• Transmucosal
• Targeted
• Sustained-released agents
• Prodrugs
• Implants 
• Intrauterine devices
• Oral

Targeted drug delivery is the most significant player within this space, and generated $x billion globally in 2014. Currently, targeted drug delivery systems are indicated in specific cancers, diabetes, tuberculosis and also cardiovascular disorders. These ‘nanocarriers’ are forecast to propel the advanced drug delivery space by an estimated $x million by 2021.

This report is presented as follows:

• By Company (e.g., JANSSEN, MYLAN, ACTAVIS, GLAXOSMITHKLINE, BAYER, NOVARTIS, NOVEN, LAVIPHARM, PROSTRACKEN, NITTO DENTO)
• By Geography (Global, USA)
• By Parent Market (Drug Delivery Systems, Advanced Drug Delivery Systems)
• By Sub-market (Generics, Women’s Health, Analgesics, Neuropathic Pain)

A wealth of financial data & business strategy information is provided including:

• Up-to-date company financials, sales & revenue figures
• Revenue and market forecasts
• Business model strategies for drug delivery, pharmaceutical and biotechnology companies
• Comprehensive account of company products, financials & portfolios

SWOT, Economic & Regulatory Environment specifics include:

• Key strengths, weaknesses and threats influencing leading player position within the market
• Technologies driving the market (e.g., chemical enhancers, microneedles)
• Top fastest growing market segments and emerging opportunities
• Top pharmaceutical companies within the market
• Comprehensive product portfolios, R&D activity and pipeline products
• M&A activity and future strategies of top companies
• High demand and unmet need enhances the market
• Challenges of the transdermal drug delivery market

Who should read this report?

• Pharmaceutical, biotechnology and diagnostic companies with an interest in personalized medicine
• Industry professionals and business strategists will discover key information to propel their policies
• Investors will gain inside information to dominant players in the industry and future forecasts
• Scientists will get a business perspective and industry insight into how scientific breakthroughs influence the market environment C-Suite professionals, Decision Makers, Business Development professionals

This report will tell you if the companies mentioned are:

• Strong, competitive players
• Pooling their resources for specific growth and therapeutic areas
• Investing strategically in R&D
• Have a history of strategic M&A activity

Benefits of Investing in our Cutting-Edge Reports:

• Clients receive complementary content* with mid-level and enterprise wide licences.
• Post-sale complementary consultation with senior expert analyst is included.
• Use of tables and figures in your own reports and presentations is permitted.
• Each report provides straight-talking strategic analysis & sector intelligence.
• All reports are updated each quarter to give you the most up-to-date information.

Spanning over 280 pages, “Global Transdermal Drug Delivery Market to 2020” report covering the Executive Summary, Transdermal Drug Delivery, Biomechanical and Pharmacological Elements Effecting Transdermal Drug Delivery, Transdermal Drug Delivery Technologies, How Nanotechnology is Transforming Transdermal Drug Delivery, Transdermal Drug Delivery and Disease States. The report covered companies are - 3M, AMAG Pharmaceuticals (Lumara Health, KV Pharm/Ther-Rx Corp), Actavis, Actelion, Ascend Therapeutics, Bayer, Boehringer Ingelheim, Endo International, GlaxoSmithKline, Hercon Pharmaceutical, Janssen Pharmaceuticals

For further information on this report, please visit- http://mrr.cm/4T4

Find all Drug Delivery Reports at: http://www.marketresearchreports.com/drug-delivery

Pick and Carry Crane market in India to grow at a CAGR of 18.50% over the period 2014-2019, finds new report

Report forecast the Pick and Carry Crane market in India to grow at a CAGR of 18.50 percent over the period 2014-2019.

A pick and carry crane is a type of material handling equipment and is meant to lift, shift, and place loads from one point to another. The efficiency of a pick and carry crane lies on the amount of load it can carry. Different technologies such as CAT and ZF determine the quality of a pick and carry crane. It is the most widely used material handling equipment in India. 

The report covers the present scenario and the growth prospects of the Pick and Carry Crane market in India for the period 2015-2019. To calculate the market size, the report considers revenue generated by individual companies offering pick and carry crane in India.

The Pick and Carry Crane Market in India, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the landscape of the Pick and Carry Crane market in India and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.

Key Regions

•  India

Key Vendors

•  ACE
•  ECEL
•  JCB
•  Voltas 

Other Prominent Vendors

•   Drillcon 
•  Hercules Cranes 
•  Indo Farm Equipment
•  Omega Construction Equipment 
•  Shakti Mining Equipments
•  Yagyapriyaa Construction India

Market Driver

•  Demand for High-capacity Cranes
•  For a full, detailed list, view our report

Market Challenge

•  Potential Competition from Other Cranes
•  For a full, detailed list, view our report

Market Trend

•  Rise in Public-Private Partnerships
•  For a full, detailed list, view our report

Key Questions Answered in this Report

•  What will the market size be in 2019 and what will the growth rate be?
•  What are the key market trends?
•  What is driving this market?
•  What are the challenges to market growth?
•  Who are the key vendors in this market space?
•  What are the market opportunities and threats faced by the key vendors?
•  What are the strengths and weaknesses of the key vendors?

Spanning over 55 pages, “Pick and Carry (PNC) Crane Market in India 2015-2019” report covering the Executive Summary, List of Abbreviations, Scope of the Report, Market Research Methodology, Introduction, Market Landscape, Buying Criteria, Market Growth Drivers, Drivers and their Impact, Market Challenges, Impact of Drivers and Challenges, Market Trends, Trends and their Impact, Vendor Landscape, Key Vendor Analysis. The report covered companies are – ACE, ECEL, JCB, Voltas , Drillcon , Hercules Cranes , Indo Farm Equipment, Omega Construction Equipment , Shakti Mining Equipments, Yagyapriyaa Construction India

For further information on this report, please visit- http://mrr.cm/4SF

Find all Pharma and Healthcare Reports at: http://www.marketresearchreports.com/pharma-healthcare

Global Sports Medicine Devices market to grow at a CAGR of 4.6% over the period 2014-2019, finds new report

Report forecast the Global Sports Medicine Devices market to grow at a CAGR of 4.6 percent over the period 2014-2019.

Sports medicine devices are specialized devices that are created by the unification of fitness and medicine fields to prevent sports injuries and promote rehabilitation. Sports medicine devices can be classified into surgical devices and therapeutic devices. Surgical devices comprise joint implants and arthroscopy devices, which help in reconstruction. Therapeutic devices include support and recovery devices such as braces and supports, monitoring devices, and other accessories such as wraps and tapes, disinfectant wipes, cold and heat therapy, and alcohol-based hand rub.

This report covers the present scenario and the growth prospects of the Global Sports Medicine Devices market for the period 2015-2019. To calculate the market size, the report considers the revenue generated from the sale of sports medicine devices such as arthroscopy devices, braces, fracture repair devices, orthobiologics, monitoring devices, prosthesis and joint implants, and other recovery products and accessories.

Global Sports Medicine Devices Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, Europe, the APAC region, and the ROW; it also covers the Global Sports Medicine Devices market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

Key Regions

•  Americas
•  APAC
•  Europe 
•  ROW

Key Vendors

•  Arthrex 
•  Biomet 
•  Smith & Nephew 
•  Stryker 

Other Prominent Vendors

•  BSN medical
•  Cramer Sports Medicine
•  DJO Global
•  Mitek Sports Medicine
•  Mueller Sports Medicine
•  Ottobock Healthcare
•  Wright Medical Technology
•  Zimmer 

Market Driver

•  Interest in Sports Activities
•  For a full, detailed list, view our report 

Market Challenge

•  Unfavorable Reimbursement Policies
•  For a full, detailed list, view our report

Market Trend

•  Zero-defect Reliability
•  For a full, detailed list, view our report

Key Questions Answered in this Report

•  What will the market size be in 2019 and what will the growth rate be?
•  What are the key market trends?
•  What is driving this market?
•  What are the challenges to market growth?
•  Who are the key vendors in this market space?
•  What are the market opportunities and threats faced by the key vendors?
•  What are the strengths and weaknesses of the key vendors?

Spanning over 95 pages, “Global Sports Medicine Devices Market 2015-2019” report covering the Executive Summary, List of Abbreviations, Scope of the Report, Market Research Methodology, Introduction, Market Landscape, Market Segmentation by Product, Market Segmentation by Application, Market Segmentation by Type of Treatment, Geographical Segmentation, Buying Criteria, Market Growth Drivers, Drivers and their Impact, Market Challenges, Impact of Drivers and Challenges, Market Trends, Trends and their Impact, Vendor Landscape, Key Vendor Analysis. The report covered companies are – Arthrex , Biomet , Smith & Nephew , Stryker , BSN medical, Cramer Sports Medicine, DJO Global, Mitek Sports Medicine, Mueller Sports Medicine, Ottobock Healthcare, Wright Medical Technology, Zimmer 

For further information on this report, please visit- http://mrr.cm/4Sz

Find all Medical Devices Reports at: http://www.marketresearchreports.com/medical-devices

The French Pharmaceutical Market Expected to reach $48.2 billion in 2020, Finds New Report

France has a mature healthcare market, based on its high healthcare expenditure and pharmaceutical production. The increasingly elderly population is expected to drive the growth of the pharmaceutical market; however, an increasing focus on generics to reduce healthcare expenditure will balance this out.

The French pharmaceutical market was valued at $48.9 billion in 2008 and an estimated $45.9 billion in 2013. It is expected to grow at a Compound Annual Growth Rate (CAGR) of 0.7% from approximately $46.2 billion in 2014 to $48.2 billion in 2020.

The public health insurance system was established in 1945, and by 2011, approximately 97% of the population was covered under Statutory Health Insurance (SHI), divided into three main schemes: general, agriculture, and non-salaried and non-farming (World Bank, 2014p). This universal healthcare coverage is expected to continue to drive the French pharmaceutical market. The increasingly elderly population is also fueling pharmaceutical market growth, accounting for 17.6% of the total population in 2013 and expected to increase at a CAGR of 1.5% to 19.7% by 2020 (INSEE, 2014f).

The government is focusing on the use of generics as a cost-containment tool to reduce healthcare expenditure. It introduced a scheme in September 2012 to increase the use of generic drugs, under which patients who agree to generic substitution will not be required to pay for their drugs. The substitution rate increased from 71% to 84% in one year as a result: a cost saving of approximately €200m ($270m) (Thomson, et al., 2013). In 2008, generic drugs accounted for 9.4% of the pharmaceutical market in terms of value and 21.7% in terms of volume, increasing to an estimated 15.3% and 27.7% respectively in 2013 (ANSM, 2013). However, this is expected to act as a barrier to the growth of the pharmaceutical market.

The French medical device market was valued at $12.7 billion, which increased to $15.5 billion in 2013. It is projected to grow at a CAGR of 5.1% from $16.2 billion in 2014 to $21.8 billion in 2020. In 2013, In Vitro Diagnostics (IVD) accounted for 15.3% of the overall medical device market, followed by cardiovascular devices (11.4%), ophthalmic devices (10.7%), orthopedic devices (8.4%) and hospital supplies (7.4%).

A transparent and efficient regulatory system combined with organizational reforms in the national regulatory agency will attract the trust of pharmaceutical and medical device companies and positively influence the French healthcare market.

In France, the National Security Agency of Medicines and Health Products (Agence Nationale de Sécurité du Médicament et des Produits de Santé, ANSM) is the main regulatory authority for pharmaceutical products and medical devices. It came into existence on May 1, 2012 when it replaced the French Agency for the Safety of Health Products (Agence Française de Sécurité Sanitaire des Produits de Santé, AFSSAPS). Its scope has been extended to include monitoring authorized medicines, promoting quick access to innovative drugs, and promoting academic research on medicine safety.

The ANSM authorizes product approvals under the national or community procedure through the European Medicines Agency (EMA) and issues licenses for manufacturing, importing, exporting, and conducting clinical trials. Approval for new drugs or medical devices requires the execution of Good Manufacturing Practice (GMP) and compliance reviews by the ANSM. The ANSM also plays a crucial role in assessing the benefits and risks associated with the safe use of health products. It maintains transparency by publishing committee proceedings, agendas, minutes and all drug withdrawals online. Legally, assigning broad responsibility is expected to increase the industry’s trust in the regulatory system and provide professionals and the public with information which will facilitate decision-making regarding any new Marketing Authorizations (MAs) (ANSM, 2014a).

The French healthcare system offers universal insurance coverage, but the economic crisis and high public debt are forcing the government to cut healthcare reimbursement.

The French healthcare system is well-developed and offers universal healthcare coverage to all citizens. The public insurance system is built on the principle that everyone must contribute to the health insurance scheme according to their income and receive care according to their needs, regardless of their place of residence. By 2011, approximately 100% of the population was covered under SHI, which covers a broad range of basic medical services such as hospital care, rehabilitation or physiotherapy, ambulatory care and diagnostic services. Healthcare expenditure is rising due to the large and growing elderly population, and the government introduces periodic reforms to address this. Cost-cutting measures in 2011 included drug price cuts and the strengthening of generic provision. In 2011, the government reduced the reimbursement rate for non-serious disease to 30%, down from 35% in 2010 (PPRI, 2012).

The market for complementary Private Health Insurance (PHI) also is well-developed, and covers user charges that are not eligible for reimbursement by SHI, such as co-payments for psychologist or dietician consultations. In 2012, SHI covered approximately 95% of the population (Thomson et al., 2012).

Political instability, a rising unemployment rate and net debt and falling GDP are affecting the economy, but government initiatives are expected to bring stability.

France was the world’s fifth-largest economy in 2013 with a Gross Domestic Product (GDP) of $2.7 trillion, placing it below the US, China, Japan and Germany (IMF, 2014a). In 2013, it was the second-largest economy in Europe behind its main economic partner, Germany (CIA, 2014).

In France, the unemployment rate increased from 7.4% in 2008 to an estimated 10.6% in 2013 (World Bank, 2014a). In 2013, there were approximately 2,481,000 people unemployed, representing an unemployment rate of 9.3% of the working population (INSEE, 2014m). The overall increase in the unemployment rate is due to the eurozone crisis and resultant drop in major industrial activity.

Government net debt amounted to approximately $2.4 trillion in 2013, having increased by approximately $636 billion from 2008 at a CAGR of 6.4% due to the high unemployment rate and increased healthcare expenditure, forming a barrier to economic growth. In 2008, GDP per capita was $45,789, which decreased to $43,000 in 2013 at a negative CAGR of 1.2% due to the global economic downturn and subsequent reduction in economic activity (IMF, 2014b). This indicates the decreasing size of the economy, related to the monetary value of all production activities.

The government is taking steps to improve economic conditions, having released a stimulus package in February 2009 of approximately $33 billion, intended to boost growth and employment through investment in infrastructure projects and tax relief for the business sector (BBC, 2008). It has also made changes to monetary policies and taxation by increasing the top corporate and personal tax rates (CIA, 2014).

For further information on this report, please visit- http://mrr.cm/4SG

Find all Pharma and Healthcare Reports at: http://www.marketresearchreports.com/pharma-healthcare